First Turn Management LLC Makes New Investment in Harrow, Inc. (NASDAQ:HROW)

First Turn Management LLC acquired a new position in shares of Harrow, Inc. (NASDAQ:HROW) during the 3rd quarter, according to its most recent 13F filing with the SEC. The firm acquired 326,582 shares of the company’s stock, valued at approximately $14,683,000. Harrow accounts for 2.3% of First Turn Management LLC’s investment portfolio, making the stock its 22nd biggest position. First Turn Management LLC owned about 0.92% of Harrow as of its most recent filing with the SEC.

Several other institutional investors also recently bought and sold shares of HROW. Mirae Asset Global Investments Co. Ltd. increased its holdings in shares of Harrow by 21.5% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,283 shares of the company’s stock valued at $57,000 after acquiring an additional 227 shares during the period. The Manufacturers Life Insurance Company increased its holdings in shares of Harrow by 5.0% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 11,865 shares of the company’s stock valued at $248,000 after acquiring an additional 567 shares during the period. Quest Partners LLC purchased a new position in shares of Harrow in the 3rd quarter valued at $29,000. Price T Rowe Associates Inc. MD grew its stake in Harrow by 6.6% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 16,672 shares of the company’s stock worth $221,000 after buying an additional 1,033 shares during the last quarter. Finally, nVerses Capital LLC acquired a new position in Harrow during the 2nd quarter valued at about $33,000. 72.76% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

HROW has been the topic of a number of recent analyst reports. Lake Street Capital upped their price target on shares of Harrow from $45.00 to $55.00 and gave the company a “buy” rating in a research note on Friday, October 4th. Craig Hallum lifted their price target on Harrow from $45.00 to $65.00 and gave the stock a “buy” rating in a research report on Friday, October 4th. Finally, B. Riley reissued a “buy” rating and issued a $50.00 price objective on shares of Harrow in a report on Thursday, August 29th.

Harrow Price Performance

Shares of HROW opened at $37.97 on Tuesday. The business’s 50-day moving average is $47.92 and its two-hundred day moving average is $32.58. The company has a quick ratio of 1.44, a current ratio of 1.55 and a debt-to-equity ratio of 3.23. Harrow, Inc. has a fifty-two week low of $8.72 and a fifty-two week high of $59.23.

Harrow Profile

Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.